Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Rises By 7.2%

AstraZeneca PLC (OTCMKTS:AZNCFGet Free Report) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 262,200 shares, an increase of 7.2% from the January 15th total of 244,700 shares. Based on an average trading volume of 5,700 shares, the short-interest ratio is currently 46.0 days.

AstraZeneca Stock Down 0.2 %

AZNCF opened at $148.71 on Monday. The business has a 50-day moving average of $135.84 and a 200-day moving average of $146.11. AstraZeneca has a fifty-two week low of $120.64 and a fifty-two week high of $175.00.

AstraZeneca Increases Dividend

The business also recently announced a dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be issued a dividend of $2.10 per share. This is a positive change from AstraZeneca’s previous dividend of $1.00. The ex-dividend date of this dividend is Wednesday, February 19th. AstraZeneca’s dividend payout ratio (DPR) is 343.14%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCFFree Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,001 shares of the company’s stock, valued at approximately $156,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Read More

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.